The possibility of using biomedical cell product in the treatment of chronic glomerulonephritis

Abstract

The basic principles of rational treatment of glomerulonephritis are considered, based on etiology, clinical manifestations and pathomorphological variants of its different forms. Today it has been established that glomerulonephritis can be primary (the etiology is usually unknown) and secondary, when the disease occurs against the background of concomitant pathology (systemic lupus erythematosus, vasculitis, hepatitis, oncological diseases, chronic viral and bacterial infections). The participation of various pathological, genetic and systemic factors in the development of various forms of glomerulonephritis has been shown. The characteristic clinical picture of manifestations of different forms of the disease and the degree of involvement of different renal structures in them are described. Against the background of the severity of the course and prevalence of various forms of glomerulonephritis, it is especially important to develop therapeutic approaches aimed at the full restoration of kidney function and cure of patients. One of such approaches is the use of biomedical cell products based on allogenic mesenchymal multipotent stromal cells and hematopoietic stromal cells. A number of studies have confirmed that the best results can be achieved with the use of cell products in complex therapies with standard treatment methods (use of cytostatics and steroid anti-inflammatory drugs) and alternative drug approaches (combination of monoclonal antibodies and polyenzyme drugs). At the same time, the use of standard and alternative techniques does not lead to a complete recovery of patients, but only transfers the course of the disease from the exacerbation phase to remission. The relevance of further development of biomedical cell products of allogeneic mesenchymal multipotent bone marrow stromal cells is shown, verification of their safety and efficacy in preclinical and clinical studies.

Keywords

biomedical cell product / hematopoietic stromal cells / glomerulonephritis / mesenchymal multipotent stromal cells / pathogenesis / therapy

References

[1] Tomilina NA, Bikbetov BT. Jepidemiologija hronicheskoj pochechnoj nedostatochnosti i novye podhody k klassifikacii i ocenke tjazhesti hronicheskih progressirujushhih zabolevanij pochek. Terapevticheskij arhiv. 2005;77(6):87–92. (In Russ.)

[2] Томилина Н.А., Бикбетов Б.Т. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболеваний почек // Терапевтический архив. 2005. № 77 (6). С. 87–92.

[3] Poulsom R. Experimental models of renal disease. Int J Exp Pathol. 2011;92:141–142. doi: 10.1111/j.1365-2613.2011.00776.x

[4] Poulsom R. Experimental models of renal disease // Int J Exp Pathol. 2011. Vol. 92. P. 141–142. doi: 10.1111/j.1365-2613.2011.00776.x

[5] Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 2014;86:905–914. doi: 10.1038/ki.2014.49

[6] Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity // Kidney Int. 2014. Vol. 86. P. 905–914. doi: 10.1038/ki.2014.49

[7] Prihodina LS, Dlin VV, Ignatova MS. Glomerulonefrit pervichnyj. Detskaja nefrologija: rukovodstvo dlja vrachej. 2011:263–268.(In Russ.)

[8] Приходина Л.С., Длин В.В., Игнатова М.С. Гломерулонефрит первичный // Детская нефрология: руководство для врачей. 2011. С. 263–268.

[9] Karras A, Jayne D. New biologics for glomerular disease on the horizon. Nephron Clin Pract. 2014;128:283–291. doi: 10.1159/000368593

[10] Karras A., Jayne D. New biologics for glomerular disease on the horizon // Nephron Clin Pract. 2014. Vol. 128. P. 283–291. doi: 10.1159/000368593

[11] Meiling J, Xie Y, Li Q, et al. Stem Cell-Based Cell Therapy for Glomerulonephritis. BioMed Research International. 2014;5:1–15. doi: 10.1155/2014/124730

[12] Meiling J., Xie Y., Li Q., et al. Stem Cell-Based Cell Therapy for Glomerulonephritis // BioMed Research International. 2014. Vol. 5. P. 1–15. doi: 10.1155/2014/124730

[13] Chadban SJ, Atkins RC. Glomerulonephritis. The Lancet. 2005;365:1797–1806. doi: 10.1016/S0140-6736(05)66583-X

[14] Chadban S.J., Atkins R.C. Glomerulonephritis // The Lancet. 2005. Vol. 365. P. 1797–1806. doi: 10.1016/S0140-6736(05)66583-X

[15] William GC. Pathogenesis and treatment of glomerulonephritis-an update. J Bras Nefrol. 2016;38:107–122. doi: 10.5935/0101-2800.20160016

[16] William G.C. Pathogenesis and treatment of glomerulonephritis-an update // J Bras Nefrol. 2016. Vol. 38. P. 107–122. doi: 10.5935/0101-2800.20160016

[17] Ar’ev AL, Izotova AB. Sovremennye predstavlenija o patogeneze idiopaticheskogo membranoznogo glomerulonefrita. Nefrologija. 2004;4:92–95. (In Russ.)

[18] Арьев А.Л., Изотова А.Б. Современные представления о патогенезе идиопатического мембранозного гломерулонефрита // Нефрология. 2004. № 4. С. 92–95.

[19] Papajan AV, Savenkova ND. Klinicheskaja nefrologija detskogo vozrasta: rukovodstvo dlja vrachej. Saint Petersbourg: Levsha; 2008. (In Russ.)

[20] Папаян А.В., Савенкова Н.Д. Клиническая нефрология детского возраста: руководство для врачей. СПб.: Левша, 2008.

[21] Floege J, Amann K. Primary glomerulonephritis. The Lancet. 2016;14:2036–2048. doi: 10.1016/S0140-6736(16)00272-5

[22] Floege J., Amann K. Primary glomerulonephritis // The Lancet. 2016. Vol. 14. P. 2036–2048. doi: 10.1016/S0140-6736(16)00272-5

[23] Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol. 2016;311(1):145–161. doi: 10.1152/ajprenal.00164.2016

[24] Chevalier R.L. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction // Am J Physiol Renal Physiol. 2016. Vol. 311, No. 1. P. 145–161. doi: 10.1152/ajprenal.00164.2016

[25] Jushina IA, Kalmykova EV, Nekipelova EV. Ocenka roli geneticheskih i immunologicheskih faktorov v formirovanii hronicheskoj pochechnoj nedostatochnosti na fone hronicheskogo glomerulonefrita. Kurskij nauchno-prakticheskij vestnik “Chelovek i ego zdorov’e”. 2008;2:117–124. (In Russ.)

[26] Юшина И.А., Калмыкова Е.В., Некипелова Е.В. Оценка роли генетических и иммунологических факторов в формировании хронической почечной недостаточности на фоне хронического гломерулонефрита // Курский научно-практический вестник «Человек и его здоровье». 2008. № 2. С. 117–124.

[27] D’Souza Z, McAdoo SP, Smith J, et al. Experimental crescentic glomerulonephritis: a new bicongenic rat model. Dis Model Mech. 2013;6:1477–1486. doi: 10.1242/dmm.012328

[28] D’Souza Z., McAdoo S.P., Smith J., et al. Experimental crescentic glomerulonephritis: a new bicongenic rat model // Dis Model Mech. 2013. Vol. 6. P. 1477–1486. doi: 10.1242/dmm.012328.

[29] Bel’skih AN, Golota AS, Krassij AB. Kletochnye tehnologii v nefrologii: sovremennoe sostojanie i perspektivy dlja voennoj mediciny. Voenno-medicinskij zhurnal. 2015;9(336):55–60. (In Russ.)

[30] Бельских А.Н., Голота А.С., Крассий А.Б., и др. Клеточные технологии в нефрологии: современное состояние и перспективы для военной медицины // Военно-медицинский журнал. 2015. № 9 (336). С. 55–60.

[31] Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease. Annu Rev Pathol. 2013;8:217–240. doi: 10.1146/annurev-pathol-011110-130216

[32] Mestecky J, Raska M, Julian BA, et al. IgA nephropathy: molecular mechanisms of the disease // Annu Rev Pathol. 2013. Vol. 8. P. 217–240. doi: 10.1146/annurev-pathol-011110-130216

[33] Jegatheesan D, Nath K, Reyaldeen R, et al. Epidemiology of biopsy-proven glomerulonephritis in Queensland adults. Nephrology. 2016;21:28–34. doi: 10.1111/nep.12559

[34] Jegatheesan D., Nath K., Reyaldeen R., et al. Epidemiology of biopsy-proven glomerulonephritis in Queensland adults // Nephrology. 2016. Vol. 21. P. 28–34. doi: 10.1111/nep.12559

[35] Shah Y, Mohiuddin A, Sluman C, et al. Rituximab in anti-glomerular basement membrane disease. QJM. 2012;105:195–197. doi: 10.1093/qjmed/hcr001

[36] Shah Y., Mohiuddin A., Sluman C., et al. Rituximab in anti-glomerular basement membrane disease // QJM. 2012. Vol. 105. P. 195–197. doi: 10.1093/qjmed/hcr001

[37] Eunkyeong J, Jeong M, Kim S, et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplantat. 2016;25:1–15. doi: 10.3727/096368915X688173

[38] Eunkyeong J., Jeong M., Kim S., et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development // Cell Transplantat. 2016. Vol. 25. P. 1–15. doi: 10.3727/096368915X688173

[39] Mariam PA, Fervenza FC, Vriese An S De, et al. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? J Nephrol. 2016;29:203–209. doi: 10.1007/s40620-015-0218-9

[40] Mariam P.A., Fervenza F.C., Vriese An.S. De, et al. C3 glomerulonephritis and autoimmune disease: more than a fortuitous association? // J Nephrol. 2016. Vol. 29. P. 203–209. doi: 10.1007/s40620-015-0218-9

[41] Jackson SJ, Steer AC, Campbell H. Systematic review: Estimation of global burden of nonsuppurative sequelae of upper respiratory tract infection: rheumatic fever and poststreptoccocal glomerulonephritis. Trop Med Int Health. 2011;16:2–11. doi: 10.1111/j.1365-3156.2010.02670.x

[42] Jackson S.J., Steer A.C., Campbell H. Systematic review: Estimation of global burden of nonsuppurative sequelae of upper respiratory tract infection: rheumatic fever and poststreptoccocal glomerulonephritis // Trop Med Int Health. 2011. Vol. 16. P. 2–11. doi: 10.1111/j.1365-3156.2010.02670.x

[43] Kanjanabuch T, Kittikowit W, Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide. Nat Rev Nephrol. 2009;5:259–269. doi: 10.1038/nrneph.2009.44

[44] Kanjanabuch T., Kittikowit W., Eiam-Ong S. An update on acute postinfectious glomerulonephritis worldwide // Nat Rev Nephrol. 2009. Vol. 5. P. 259–269. doi: 10.1038/nrneph.2009.44

[45] Couser WG, Johnson RJ. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney International. 2014;86:905–914. doi: 10.1038/ki.2014.49

[46] Couser W.G., Johnson R.J. The etiology of glomerulonephritis: roles of infection and autoimmunity // Kidney International. 2014. Vol. 86. P. 905–914. doi: 10.1038/ki.2014.49

[47] Briganti EM, Dowling J, Finlay M, et al. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant. 2001;16:1364–1367. doi: 10.1093/ndt/16.7.1364

[48] Briganti E.M., Dowling J., Finlay M., et al. The incidence of biopsy-proven glomerulonephritis in Australia // Nephrol Dial Transplant. 2001. Vol. 16. P. 1364–1367. doi: 10.1093/ndt/16.7.1364

[49] Sadovnikova IV. Vozmozhnye oslozhnenija pri steroidnoj terapii hronicheskogo glomerulonefrita v pediatricheskoj praktike. Sovremennye tehnologii v medicine. 2009;2:79–81. (In Russ.)

[50] Садовникова И.В. Возможные осложнения при стероидной терапии хронического гломерулонефрита в педиатрической практике // Современные технологии в медицине. 2009. № 2. С. 79–81.

[51] 26. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12. doi: 10.1053/ajkd.2003.50007

[52] Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey // Am J Kidney Dis. 2003. Vol. 41. P. 1–12. doi: 10.1053/ajkd.2003.50007

[53] Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrol Dial Transplant. 2019;34:193–199. doi: 10.1093/ndt/gfy220

[54] Sethi S., Fervenza F.C. Standardized classification and reporting of glomerulonephritis // Nephrol Dial Transplant. 2019. Vol. 34. P. 193–199. doi: 10.1093/ndt/gfy220

[55] Dahan K, Boffa J. Membranous Glomerulonephritis. Nephrol Dial Transplant. 2020:35(4):549–551. doi: 10.1093/ndt/gfz139

[56] Dahan K., Boffa J. Membranous Glomerulonephritis // Nephrol Dial Transplant. 2020. Vol. 35, No. 4. P. 549–551. doi: 10.1093/ndt/gfz139

[57] Mathis D, Benoist C. Back to central tolerance. Immunity. 2004;20:509–516. doi: 10.1016/s1074-7613(04)00111-6

[58] Mathis D., Benoist C. Back to central tolerance // Immunity. 2004. Vol. 20. P. 509–516. doi: 10.1016/s1074-7613(04)00111-6

[59] Si-Yang W, Bu R, Zhang Q, et al. Clinical, Pathological, and Prognostic Characteristics of Glomerulonephritis Related to Staphylococcal Infection. Medicine. 2016;95:1–7. doi: 10.1097/MD.0000000000003386.

[60] Si-Yang W., Bu R., Zhang Q., et al. Clinical, Pathological, and Prognostic Characteristics of Glomerulonephritis Related to Staphylococcal Infection // Medicine. 2016. Vol. 95. P. 1–7. doi: 10.1097/MD.0000000000003386

[61] Muhin NA. Racional’naja farmakoterapija v nefrologii. Rukovodstvo dlja praktikujushhih vrachej. Moscow: Literra; 2006. (In Russ.)

[62] Мухин Н.А. Рациональная фармакотерапия в нефрологии. Руководство для практикующих врачей. М.: Литерра, 2006.

[63] Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in the general community: the AusDiab Kidney Study. J Am Soc Nephrol. 2003;14:5131–5138. doi: 10.1097/01.asn.0000070152.11927.4a

[64] Chadban S.J., Briganti E.M., Kerr P.G., et al. Prevalence of kidney damage in the general community: the AusDiab Kidney Study // J Am Soc Nephrol. 2003. Vol. 14. P. 5131–5138. doi: 10.1097/01.asn.0000070152.11927.4a

[65] Burova LA, Gavrilova EA, Pigarevskij PV. Svjazyvanie streptokokkami gruppy A tipa M12 immunnyh kompleksov: rol’ dannogo svjazyvanija v patogeneze jeksperimental’nogo glomerulonefrita. Medicinskaja immunologija. 2006;8:124–125. (In Russ.)

[66] Бурова Л.А., Гаврилова Е.А., Пигаревский П.В., и др. Связывание стрептококками группы А типа М12 иммунных комплексов: роль данного связывания в патогенезе экспериментального гломерулонефрита // Медицинская иммунология. 2006. № 8. С. 124–125.

[67] Kudrjashov SI, Leont’eva EV, Karzakova LM. Sovremennye osobennosti kliniko-immunologicheskih projavlenij glomerulonefrita. Klinicheskaja i profilakticheskaja medicina. 2017;2:13–18. (In Russ.)

[68] Кудряшов С.И., Леонтьева Е.В., Карзакова Л.М. Современные особенности клинико-иммунологических проявлений гломерулонефрита // Клиническая и профилактическая медицина. 2017. № 2. С. 13–18.

[69] Gordeev IG, Soboleva VN, Volov NA. Varianty techenija bystroprogressirujushhego glomerulonefrita: kak i chem lechit’. Lechebnoe delo. 2018;1:26–31. (In Russ.)

[70] Гордеев И.Г., Соболева В.Н., Волов Н.А., и др. Варианты течения быстропрогрессирующего гломерулонефрита: как и чем лечить // Лечебное дело. 2018. № 1. С. 26–31

[71] Klochkov ND. Izbrannye lekcii po chastnoj patologicheskoj anatomii. Saint Petersbourg:Voenno-medicinskaja akademija imeni S.M. Kirova;1992. (In Russ.)

[72] Клочков Н.Д. Избранные лекции по частной патологической анатомии. СПб.: Военно-медицинская академия имени С.М. Кирова, 1992.

[73] Smirnov AV, Shilov EM, Kozlovskaja NL. Nefrologija. Klinicheskie rekomendacii. Moscow: GEOTAR-Media; 2020. (In Russ.)

[74] Смирнов А.В., Шилов Е.М., Козловская Н.Л. Нефрология. Клинические рекомендации. М.: ГЭОТАР-Медиа, 2020. 856 с.

[75] Smirnov AV, Dobronravov VA, Sipovskij VG. Klinicheskie rekomendacii po diagnostike, lecheniju i prognozu membranoproliferativnogo glomerulonefrita. Nefrologija. 2014;18(6):82–93. (In Russ.)

[76] Смирнов А.В., Добронравов В.А., Сиповский В.Г., и др. Клинические рекомендации по диагностике, лечению и прогнозу мембранопролиферативного гломерулонефрита // Нефрология. 2014. № 18 (6). С. 82–93.

[77] Avtonomova OI, Karzakova LM, Geranjushkina EI. Osobennosti immuno-gematologicheskih projavlenij ostrogo i hronicheskogo techenija glomerulonefrita. Vestnik Chuvashskogo universiteta. 2013;3:323–329. (In Russ.)

[78] Автономова О.И., Карзакова Л.М., Геранюшкина Е.И., и др. Особенности иммуногематологических проявлений острого и хронического течения гломерулонефрита // Вестник Чувашского университета. 2013. № 3. С. 323–329.

[79] Novakova ON, Nekipelova EV, Jakunchenko TI. Rol’ genov-kandidatov v progressirovanii hronicheskogo glomerulonefrita. Nauchnye vedomosti. Serija Medicina. Farmacija. 2016;12:118–123. (In Russ.)

[80] Новакова О.Н., Некипелова Е.В., Якунченко Т.И., и др. Роль генов-кандидатов в прогрессировании хронического гломерулонефрита // Научные ведомости. Серия Медицина. Фармация. 2016. № 12. С. 118–123.

[81] Shulutko BI, Makarenko SV. Ostryj glomerulonefrit, i ne tol’ko, v XXI veke. Nefrologija. 2015;6(19):14–19. (In Russ.)

[82] Шулутко Б.И., Макаренко С.В. Острый гломерулонефрит, и не только, в XXI веке // Нефрология. 2015. № 6 (19). С. 14–19.

[83] Muravleva LE, Molotov-Luchanskij VB, Kljuev DA. Gemostaz pri hronicheskoj bolezni pochek. Sovremennye problemy nauki i obrazovanija. 2010;4:36–42. (In Russ.)

[84] Муравлева Л.Е., Молотов-Лучанский В.Б., Клюев Д.А. Гемостаз при хронической болезни почек // Современные проблемы науки и образования. 2010. № 4. С. 36–42

[85] Muhin IV. Sravnitel’naja jeffektivnost’ lechenija hronicheskogo glomerulonefrita. Nefrologija. 2001;1:35–38. (In Russ.)

[86] Мухин И.В. Сравнительная эффективность лечения хронического гломерулонефрита // Нефрология. 2001. № 1. С. 35–38.

[87] Kudaeva OT, Gojman EV, Nenasheva EV. Korrekcija autoimmunnogo glomerulonefrita u jeksperimental’nyh zhivotnyh letal’nym oblucheniem i perenosom kletok singennogo kostnogo mozga. Medicinskaja immunologija. 2010;12(3):191–198. (In Russ.)

[88] Кудаева О.Т., Гойман Е.В., Ненашева Е.В., и др. Коррекция аутоиммунного гломерулонефрита у экспериментальных животных летальным облучением и переносом клеток сингенного костного мозга // Медицинская иммунология. 2010. № 3 (12). С. 191–198.

[89] Weiping H, Huang G, Cao X, et al. Suppression of experimental autoimmune glomerulonephritis by tryptophan. J Nephrol. 2014;27:19–28. doi: 10.1007/s40620-013-0020-5

[90] Weiping H., Huang G., Cao X., et al. Suppression of experimental autoimmune glomerulonephritis by tryptophan // J Nephrol. 2014. Vol. 27. P. 19–28. doi: 10.1007/s40620-013-0020-5

[91] Liu G, David BT, Trawczynski M, et al. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications. Stem Cell Rev Rep. 2020;16(1):3–32. doi: 10.1007/s12015-019-09935-x

[92] Liu G., David B.T., Trawczynski M., et al. Advances in Pluripotent Stem Cells: History, Mechanisms, Technologies, and Applications // Stem Cell Rev Rep. 2020. Vol. 16, No. 1. P. 3–32. doi: 10.1007/s12015-019-09935-x

[93] Zhao L, Chen S, Yang P, et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease. Stem Cell Res Ther. 2019;10:182–195. doi: 10.1186/s13287-019-1287-9

[94] Zhao L., Chen S., Yang P., et al. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease // Stem Cell Res Ther. 2019. Vol. 10. P. 182–195. doi: 10.1186/s13287-019-1287-9

[95] Korjakova NN. Patogeneticheskie osobennosti razlichnyh kliniko-morfologicheskih variantov hronicheskogo glomerulonefrita. Nefrologija. 2005;9:58–62. (In Russ.)

[96] Корякова Н.Н. Патогенетические особенности различных клинико-морфологических вариантов хронического гломерулонефрита // Нефрология. 2005. № 9. С. 58–62.

[97] Caldas HC, Couto T, Fernandes I et al. Comparative effects of mesenchymal stem cell therapy in distinct stages of chronic renal failure. Clin Exp Nephrol. 2015;19:783–789. doi: 10.1007/s10157-015-1079-1

[98] Caldas H.C., Couto T., Fernandes I., et al. Comparative effects of mesenchymal stem cell therapy in distinct stages of chronic renal failure // Clin Exp Nephrol. 2015. Vol. 19. P. 783–789. doi: 10.1007/s10157-015-1079-1

[99] Reynolds J. Strain differences and the genetic basis of experimental autoimmune anti-glomerular basement membrane glomerulonephritis. Int J Exp Pathol. 2011;92:204–210. doi: 10.1111/j.1365-2613.2011.00763.x

[100] Reynolds J. Strain differences and the genetic basis of experimental autoimmune anti-glomerular basement membrane glomerulonephritis // Int J Exp Pathol. 2011. Vol. 92. P. 204–210. doi: 10.1111/j.1365-2613.2011.00763.x

[101] Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol. 2014;26:502–509. doi: 10.1097/BOR.0000000000000089

[102] Schwartz N., Goilav B., Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis // Curr Opin Rheumatol. 2014. Vol. 26. P. 502–509. doi: 10.1097/BOR.0000000000000089

[103] Eunkyeong J, Jeong M, Kim S, et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development. Cell Transplantation. 2016;25:1–15. doi: 10.3727/096368915X688173

[104] Eunkyeong J., Jeong M., Kim S., et al. Infusion of Human Bone Marrow-Derived Mesenchymal Stem Cells Alleviates Autoimmune Nephritis in a Lupus Model by Suppressing Follicular Helper T-Cell Development // Cell Transplantation. 2016. Vol. 25. P. 1–15. doi: 10.3727/096368915X688173

[105] Dandan W, Zhang H, Liang J, et al. Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience. Cell Transplantation. 2013;22:2267–2277. doi: 10.3727/096368911X582769c

[106] Dandan W., Zhang H., Liang J., et al. Allogeneic Mesenchymal Stem Cell Transplantation in Severe and Refractory Systemic Lupus Erythematosus: 4 Years of Experience // Cell Transplantation. 2013. Vol. 22. P. 2267–2277. doi: 10.3727/096368911X582769c

[107] Chen C, Liang J, Yao G, et al. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients. International Immunopharmacology. 2017;44:234–241. doi: 10.1016/j.intimp.2017.01.024

[108] Chen C., Liang J., Yao G., et al. Mesenchymal stem cells upregulate Treg cells via sHLA-G in SLE patients // International Immunopharmacology. 2017. Vol. 44. P. 234–241. doi: 10.1016/j.intimp.2017.01.024

[109] Shuk-Man K, Sytwu H, Chang D, et al. Decoy Receptor 3 Ameliorates an Autoimmune Crescentic Glomerulonephritis Model in Mice. J Am Soc Nephrol. 2007;18:2473–2485. doi: 10.1681/ASN.2006111242

[110] Shuk-Man K., Sytwu H., Chang D., et al. Decoy Receptor 3 Ameliorates an Autoimmune Crescentic Glomerulonephritis Model in Mice // J Am Soc Nephrol. 2007. Vol. 18. P. 2473–2485. doi: 10.1681/ASN.2006111242

[111] Nagai H, Takizawa T, Nishiyori T, et al. Experimental glomerulonephritis in mice as a model for immunopharmacological studies. Japan. J Pharmacol. 1982;32:1117–1124. doi: 10.1254/jjp.32.1117

[112] Nagai H., Takizawa T., Nishiyori T., et al. Experimental glomerulonephritis in mice as a model for immunopharmacological studies // Japan J Pharmacol. 1982. Vol. 32. P. 1117–1124. doi: 10.1254/jjp.32.1117

[113] Hiramatsu R, Ubara Y, Sawa N, et al. Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis. Human Pathology. 2016;50:187–194. doi: 10.1016/j.humpath.2015.12.005

[114] Hiramatsu R., Ubara Y., Sawa N., et al. Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis // Human Pathology. 2016. Vol. 50. P. 187–194. doi: 10.1016/j.humpath.2015.12.005

[115] Chang A, Hingorani S, Kowalewska J, et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol. 2007;2:1014–1023. doi: 10.2215/CJN.01700407

[116] Chang A., Hingorani S., Kowalewska J., et al. Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature // Clin J Am Soc Nephrol. 2007. Vol. 2. P. 1014–1023. doi: 10.2215/CJN.01700407

[117] Kemper MJ, Güngör T, Halter J, et al. Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation. Clin Nephrol. 2007;67:5–11. doi: 10.5414/cnp67005

[118] Kemper M.J., Güngör T., Halter J., et al. Favorable long-term outcome of nephrotic syndrome after allogeneic hematopoietic stem cell transplantation // Clin Nephrol. 2007. Vol. 67. P. 5–11. doi: 10.5414/cnp67005

RIGHTS & PERMISSIONS

Sigareva L.P., Kokorina A.A., Kondartenko A.A., Slizhov P.A., Ekaterina E.V., Alexandrov V.N., Solovyov A.A.